Abstract:Background: Senomorphics have been considered as an effective alternative paradigm of senotherapeutics to regulate cellular senescence and related disorders by inhibiting the deleterious effects of senescence-associated secretory phenotype (SASP) components secreted by senescent cells without inducing cell death. However, current senomorphic drugs usually exhibit low selectivity towards senescent cells and inevitably cause unwanted side effects, highlighting the need to develop innovative senomorphic strategies for the specific regulation of cellular senescence. Methods: To address this challenge, here we design a novel class of senomorphics with active cell targeting and activatable activities for selective regulation of SASP by conjugating a senescent cell-targeted aptamer with a SA-β-gal-activated H2S donor. Using senescent BJ cells as a cell model, a series of investigations were performed to evaluate the performance of the engineered senomorphic (Apt-H2SD) for cell-specific regulation of SASP during cellular senescence. Results: Apt-H2SD demonstrated specific binding and accumulation to senescent cells over proliferating cells through the aptamer-mediated cell targeting. Upon internalization, Apt-H2SD was efficiently activated by the accumulated SA-β-gal in senescent cells, leading to the release of H2S precursor and subsequently suppressing the expression of three important SASP factors (IL-6, IL-1β and MMP3) at the mRNA level. Conclusion: Our results strongly support the potential of Apt-H2SD as a valuable senomorphic. With rational design of the molecular structure, this study may provide a general strategy to construct advanced senescencetargeted activatable senomorphics for precise intervention of cellular senescence and age-related diseases.

Spatially Confined Intervention of Cellular Senescence by a Lysosomal Metabolism Targeting Molecular Prodrug for Broad-Spectrum Senotherapy

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Senolytic Prodrugs: A Promising Approach to Enhancing Senescence-Targeting Intervention

Photoactivatable senolysis with single-cell resolution delays aging

Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies

Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice

Senolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Engineering Hierarchical Recognition-Mediated Senolytics for Reliable Regulation of Cellular Senescence and Anti-Atherosclerosis Therapy

A senolytic strategy integrating multiple technologies delays aging

Advances in Nanotherapy for Targeting Senescent Cells

Targeted Delivery Strategy: A Beneficial Partner for Emerging Senotherapy

Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development

Targeted Regulation of Senescence-Associated Secretory Phenotype with an Aptamer-Conjugated Activatable Senomorphic

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

A Senolysis-Based Theragnostic Prodrug Strategy Towards Chronic Renal Failure

A precise dual-drug codelivery nanosystem for treating kidney failure by eliminating senescent cells

An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety

Discovery and Repurposing of Multi-Target Senolytics through Structure-Based Virtual Screening

A versatile drug delivery system targeting senescent cells